乳腺癌端粒酶活性的研究  

Telomerase activity in breast carcinoma

作　　者：杨文涛[1] 许良中[1] 张泰明[1] 朱伟萍[1] 李小妹[1] 金爱萍[1] 何开玲[1] 

机构地区：[1]上海医科大学肿瘤医院分子病理研究室,200032

出　　处：《中华肿瘤杂志》1999年第4期278-280,共3页Chinese Journal of Oncology

摘　　要：目的　探讨乳腺癌中端粒酶活性的意义及其与腋窝淋巴结状态的关系。方法　用建立在多聚酶链反应（ＰＣＲ） 基础上的端粒重复序列扩增法（ＴＲＡＰ） ，对８８ 例乳腺癌和１６ 例乳腺良性疾病进行端粒酶活性检测。结果　８８ 例乳腺癌中，７５ 例（８５２％ ） 检测到端粒酶活性（ 其中３ 例导管内癌端粒酶均为阳性） ，而在１６ 例乳腺良性疾病中仅２ 例（１２５％ ） 端粒酶阳性，两组的差异有显著性（ Ｐ＜０００１）。此外，端粒酶活性在淋巴结阳性的乳腺癌（９３２％ ） 中显著高于淋巴结阴性者（７７３ ％ ，Ｐ＜００５） 。结论　端粒酶活化在乳腺癌的发生过程中起重要作用，且有可能成为乳腺癌发生的早期指标。Objective To investigate the significance of telomerase activity in breast carcinoma with respect to axillary lymph node status. Methods Telomerase activity was analyzed in 88 breast carcinomas specimens and 16 benign breast lesions, using PCR based telomeric repeat amplification protocol (TRAP) assay.Results Telomerase activity was detected in 75 (85.2%) of 88 breast carcinomas (including three breast carcinomas in situ which were all positive for telomerase activity), whereas in benign breast lesions analyzed only 2 (12.5%) of 16 cases were positive ( P <0.001). Besides, telomerase activity was significantly higher in node positive breast carcinomas (93.2%) than in node negative ones (77.3%, P <0 05). Conclusion The results suggest that telomerase activation plays an important role during breast carcinoma progression. It may serve as an early marker of breast carcinoma.

关 键 词：乳腺癌 端粒酶 病理学 TRAP 

分 类 号：R737.9[医药卫生—肿瘤]